Antibody CDMO Market Size To Reach $58.40 Billion By 2030

Antibody CDMO Market Growth & Trends

The global antibody CDMO market is expected to reach USD 58.40 billion by 2030, expanding at a CAGR of 14.0% from 2023 to 2030, according to a new report by Grand View Research, Inc. Increasing R&D activities pertaining to the discovery of novel antibody therapeutics, growing prevalence of cancer cases and rising collaborations amongst contract development & manufacturing organizations (CDMO) and biopharmaceutical companies are the key factors driving the growth of antibody CDMO market.

Antibodies are drug therapies, especially used in cancer treatment. These antibodies do not affect healthy cells in the body and improve the therapeutic index of the drug; these are two key reasons for the high demand for antibodies in the treatment of cancer. These factors have supported the development of antibody types such as Antibody-drug conjugates (ADCs) in clinical research.

Owing to the efficiency of antibodies in cancer treatment, biopharmaceutical companies are receiving a significant amount of funding for conducting antibody-related research. For instance, in October 2022, Mablink Bioscience raised USD 31 million from Series A funding to build its antibody ADC pipeline for cancer treatment. Similarly, in July 2021, ProfoundBio received USD 55 million from investors to accelerate the development of the antibody ADC pipeline. Hence, increasing efforts via biopharmaceutical companies to develop novel therapeutics pertaining to the treatment of cancer is one of the major factors supporting the market growth.

The COVID-19 pandemic had a considerable impact on the market. However, several players adopted in-organic strategic initiatives such as partnerships, mergers, and acquisitions to mitigate the impact of the pandemic and thereby witness a rebound in their sales revenue. Moreover, the geopolitical war between Ukraine and Russia has negatively impacted the antibody CDMO market, as clinical trials outsourced across the war-infected countries have been halted until further notice. This has greatly impacted certain countries, such as the U.S., due to which the overall global market has witnessed a moderate dip in its revenue during 2022.

 Request a free sample copy or view report summary: Antibody CDMO Market Report

Antibody CDMO Market Report Highlights

• Monoclonal antibodies segment accounted for the largest share of 67.6% in 2022.The segment is driven by growing demand for anti-cancer-based monoclonal antibody treatment therapeutics, constituting a vast portion of the overall antibody therapeutics

• Based on the source, the mammalian segment accounted for the largest share of 58.5% in 2022. High shares of the segment are majorly due to increasing rates of outsourcing witnessed across mammalian antibody therapeutics, as the cost of production of such antibodies is significantly high. Hence, CDMOs offer these manufacturing services at a comparatively lower cost than in-house production rates, thus supporting its large segment share in the market

• The immune-mediated disorders segment is anticipated to register the fastest CAGR of 14.6% during the forecast period. This is due to the growing rate of clinical trials targeted at discovering novel antibodies in the treatment of immune-mediated disorders

• Biopharmaceutical companies are anticipated to register the fastest CAGR of 14.3% from 2023 to 2030, owing increasing number of biopharmaceutical companies focusing on producing novel antibody therapeutics, thus supporting its lucrative growth during the forecast period

• Asia Pacific is anticipated to witness the highest CAGR of 14.2% during the forecast time frame. High growth is majorly due to Asian countries such as India and China, where the cost of production is comparatively lower than in Western economies, thus attracting a larger customer base across the region and thereby supporting the region’s growth

Antibody CDMO Market Segmentation

Grand View Research has segmented the global antibody CDMO market based on product, source, therapeutic area, end-use, and region:

Antibody CDMO Product Outlook (Revenue, USD Million, 2018 - 2030)

• Monoclonal Antibodies

• Polyclonal Antibodies

• Others

Antibody CDMO Source Outlook (Revenue, USD Million, 2018 - 2030)

• Mammalian

• Microbial

Antibody CDMO Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)

• Oncology

• Neurology

• Cardiology

• Infectious Diseases

• Immune-mediated Disorders

• Others

Antibody CDMO End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Biopharmaceutical Companies

• Research Laboratories

• Others

Antibody CDMO Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.                

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Antibody CDMO Market

• Lonza

• Catalent, Inc

• Samsung Biologics

• WuXi Biologics

• AGC Biologics

• AbbVie Inc.

• Boehringer Ingelheim International GmbH

• Charles River Laboratories

• FUJIFILM Holdings Corporation

• mAbxience